This clinical trial is focused on studying the effectiveness of a treatment called Ozone therapy for patients experiencing pain due to chemotherapy-induced peripheral neuropathy. This condition is a type of nerve damage that can occur after chemotherapy, leading to pain and discomfort. The treatment being tested involves using a special mixture of gases, primarily made up of oxygen, with a small amount of ozone. The purpose of the study is to see if adding ozone therapy to the usual care can help reduce pain and improve the quality of life for these patients.

Participants in the study will receive either the ozone therapy or a placebo, which is a substance with no active therapeutic effect. The study is designed to be triple-blind, meaning that neither the participants, the healthcare providers, nor the researchers know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The treatment will be administered rectally, which means it is given through the rectum. The study will last for a period of time, during which participants will be monitored for changes in their pain levels and overall health.

The main goal is to assess how the addition of ozone therapy affects pain and self-perceived health-related quality of life. The study will also look at the cost-effectiveness of this treatment, meaning it will evaluate whether the benefits of the therapy justify the costs involved. Participants’ quality of life will be measured using questionnaires, and other factors like anxiety, depression, and nerve function will also be assessed. The study aims to provide valuable information on whether ozone therapy can be a beneficial addition to the standard management of pain in patients with chemotherapy-induced peripheral neuropathy.